Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
APPA-02 by Armata Pharmaceuticals for Bronchiectasis: Likelihood of Approval
APPA-02 is under clinical development by Armata Pharmaceuticals and currently in Phase II for Bronchiectasis. According to GlobalData, Phase II...
Data Insights
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals's APPA-02?
APPA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Resistant Pseudomonas aeruginosa Infections. According...